This episode focuses on anticholinesterase agents as a distinctive pharmacological strategy: rather than stimulating receptors directly, these drugs extend the life of an endogenous signal. By inhibiting acetylcholinesterase, they increase acetylcholine availability at synapses and neuromuscular junctions, sharpening or overwhelming physiological effects depending on dose and context. We explore how this indirect mechanism explains both their therapeutic power and their narrow safety margins.

Key takeaways you’ll build and reuse throughout the series:

* Enzyme inhibition as signal amplification: why prolonging neurotransmitter action differs fundamentally from receptor agonism.

* Reversible versus irreversible inhibition: time, binding, and recovery as clinical variables.

* Sites of action matter: central synapses, autonomic junctions, and the neuromuscular junction respond differently to the same increase in acetylcholine.

* Therapeutic uses grounded in mechanism: myasthenia gravis, glaucoma, ileus, and central cognitive disorders.

* Toxicity as excess physiology: recognising cholinergic overload and reasoning through management principles.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe